Does Bioma Probiotic Work for Weight Loss? Evidence Review of the Strains, the Meta-Analyses, and Honest Magnitudes

TL;DR

Bioma probiotic is a dietary supplement, not a weight-loss drug. The official site (bioma.health) markets a proprietary blend of Bifidobacterium lactis, B. longum, and B. breve (90 mg total) with 100 mg xylooligosaccharide (XOS) prebiotic and 90 mg tributyrin postbiotic, priced at $47.99 per bottle (60 capsules, 30-day supply) or as low as $26.94 per bottle on the 6-month subscription. The brand does NOT disclose specific strain identifiers (e.g., Bb-12, HN019, B420) for its core probiotic, and does NOT cite any published RCT of its specific branded formulation.

What the verified probiotic + weight evidence actually shows. Three large pooled analyses are the relevant reference:

• Borgeraas 2018 (PMID 29047207, Obesity Reviews) — meta-analysis of 15 RCTs and 957 overweight/obese adults: pooled body weight reduction approximately 0.6 kg and BMI reduction approximately 0.27 kg/m².
• Sadeghi 2024 (PMID 39320636, Probiotics and Antimicrobial Proteins) — umbrella review pooling 17 systematic reviews: pooled body weight reduction approximately 0.51 kg and BMI reduction approximately 0.30 kg/m².
• Rasaei 2024 (PMID 38572479, Frontiers in Endocrinology) — umbrella review of prebiotic, probiotic, and synbiotic effects: similar small-but-real magnitudes.

The strongest single-trial result is Stenman 2016 (PMID 27810310, EBioMedicine) — a 6-month trial of B. animalis ssp. lactis 420 + polydextrose in 225 overweight adults that produced a 4.5% body-fat-mass reduction (approximately 1.4 kg of fat) and waist-circumference reductions, but did NOT achieve statistically significant body-weight reductions. The B420 strain studied is NOT one of the strains disclosed on Bioma's label.

The Akkermansia muciniphila pilot — Depommier 2019 (PMID 31263284, Nature Medicine), n=32, 3 months — reported a non-significant body weight trend (-2.27 kg vs placebo, P > 0.05) but significant improvements in insulin sensitivity. Bioma sells a separate GLP-1 Booster product containing 10 mg Akkermansia muciniphila per serving.

For order-of-magnitude context, FDA-approved anti-obesity medications produce:

• Wegovy (semaglutide 2.4 mg weekly) — ~15% total body weight loss over 68 weeks per STEP-1 (Wilding 2021, PMID 33567185, NEJM)
• Zepbound (tirzepatide 15 mg weekly) — ~21% TBWL over 72 weeks per SURMOUNT-1 (Jastreboff 2022, PMID 35658024, NEJM)

The order-of-magnitude gap between Bioma's expected effect (~0.5-1 kg over months) and Wegovy/Zepbound efficacy (~14-21 kg) is approximately 20-30 fold. Bioma is not a primary weight-loss intervention. It is a dietary supplement sold under DSHEA 1994 with the standard disclaimer: “This product is not intended to diagnose, treat, cure, or prevent any disease.”

1. What Bioma actually is

Bioma is a direct-to-consumer probiotic brand sold through bioma.health, on Amazon, and on Walmart. The flagship product is the Bioma Digestive Health Probiotic (60 delayed-release capsules per bottle, 30-day supply at two capsules per day). The brand has since expanded to a line of related products:

The flagship Digestive Health Probiotic is the product most associated with the “Bioma” brand name and is the focus of this article, with notes on the GLP-1 Booster where it overlaps the weight-management positioning.

1.1 Pricing (May 2026, bioma.health official)

The official site offers a 14-day money-back guarantee — notably shorter than the 30-day money-back guarantees common in the supplement industry, and far shorter than the 6-month timeframe used in the relevant probiotic + weight trials (Stenman 2016 was a 6-month study). 14 days is not enough time to evaluate gut-microbiome composition shifts, which generally require 8-12 weeks of consistent intake to demonstrate measurable changes in stool short-chain fatty acids or 16S rRNA bacterial abundances.

1.2 What the official site claims (verbatim)

From the Bioma.health home page and weight-loss-probiotics page, quoted directly:

• “Powerful weight-loss boost”
• “probiotics like Bifidobacterium lactis and Bifidobacterium breve can significantly aid in weight management”
• “healthy microbiome will boost metabolism and digestion to block excess fat storage”
• “support digestion, control appetite, and improve metabolism—helping you manage weight naturally”
• “influence fat storage, digestion, and appetite”
• “Reducing Belly Fat” / “reduce bloating and helping your body process fat efficiently”
• “regulate hunger hormones, reducing cravings”
• “balanced gut helps your body use energy efficiently”

The marketing language closely mirrors the structure of FTC-flagged weight-loss advertising patterns (“boost metabolism,” “reduce fat storage,” “target belly fat”) and uses the standard escape hatches (“may,” “can help,” “naturally”) that keep claims short of the DSHEA structure-function violation line. The site DOES carry the mandatory DSHEA disclaimer:

“Content and statements on this website have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. It should not be substituted for medical advice or medical intervention.”

That disclaimer is the most important sentence on the entire website. It is the regulatory acknowledgment that Bioma is sold as a food-class product, NOT a drug, and that no FDA review of its efficacy has occurred. The disclaimer applies to every claim on every page of bioma.health.

2. The strain-disclosure problem

Probiotic effects are strain-specific, not species-specific. The same species (e.g., Bifidobacterium animalis ssp. lactis) can include strains with markedly different documented effects:

Bioma's Digestive Health Probiotic facts panel discloses three species (B. lactis, B. longum, B. breve) within a 90 mg “Proprietary Probiotic Blend.” The specific strain identifiers are NOT printed on the label or the product page. The Feminine Health and GLP-1 Booster products DO disclose some strain IDs (Bb-18, HN001, La-14, Ll-23, Lg-36, Bl-05) — making the absence of strain disclosure on the flagship product more noticeable, not less.

Why this matters for consumers: there is a large difference between “Bioma uses B. lactis, and Stenman 2016 used B. lactis 420, therefore Bioma should work like Stenman” and the verified scientific claim. B. lactis in the Bioma blend may be Bb-12, HN019, Bi-07, Bb-18, B420, or some other strain. Each strain has a different documented effect profile. Without strain disclosure, consumers cannot map Bioma to specific peer-reviewed evidence. The fair reading is that Bioma sells a genus-level probiotic with general gut-health properties common to the Bifidobacterium class — not a body-fat-targeted formulation backed by specific trial data.

3. The probiotic + weight meta-analysis evidence

Three large pooled analyses define the realistic expectation for any probiotic + body weight intervention. All three were verified via PubMed E-utilities on 2026-05-15.

3.1 Borgeraas 2018 (Obesity Reviews)

Borgeraas and colleagues (2018, PMID 29047207, Obesity Reviews) conducted a systematic review and meta-analysis of randomized controlled trials evaluating probiotic supplementation in adults with overweight or obesity. The analysis pooled 15 RCTs comprising 957 participants and reported:

• Body weight: small but statistically significant pooled reduction of approximately 0.6 kg favoring probiotics over placebo
• BMI: pooled reduction of approximately 0.27 kg/m²
• Fat mass: pooled reduction of approximately 0.6 kg
• Fat percentage: small reductions reported across the trials reporting this outcome

The strains pooled across the 15 RCTs were heterogeneous — Lactobacillus species, Bifidobacterium species, multispecies blends, and synbiotic (probiotic + prebiotic) combinations. Trial durations ranged from 3 weeks to 24 weeks. The authors' conclusion was that probiotic supplementation produces modest but statistically significant reductions in body weight and BMI in overweight/obese adults, with meaningful heterogeneity across interventions.

3.2 Sadeghi 2024 (Probiotics and Antimicrobial Proteins)

Sadeghi and colleagues (2024, PMID 39320636, Probiotics and Antimicrobial Proteins) performed an umbrella review and subgroup meta-analysis pooling 17 prior systematic reviews of probiotic supplementation in overweight or obese adults. Key findings:

• Pooled body weight reduction: approximately 0.51 kg, consistent with Borgeraas 2018
• Pooled BMI reduction: approximately 0.30 kg/m²
• Subgroup effects: larger effects observed in trials >8 weeks duration, in multi-strain interventions, and in participants with higher baseline BMI

The authors note that probiotic supplementation is associated with modest reductions in adiposity indicators in overweight/obese individuals and that the effect varies meaningfully by strain composition, trial duration, and baseline characteristics.

3.3 Rasaei 2024 (Frontiers in Endocrinology)

Rasaei and colleagues (2024, PMID 38572479, Frontiers in Endocrinology) performed an umbrella review of meta-analyses of prebiotic, probiotic, and synbiotic supplementation on overweight/obesity indicators. The pooled effects fell in the same general range as Borgeraas and Sadeghi: small but real reductions in body weight, BMI, waist circumference, and fat percentage. Synbiotic interventions (probiotic + prebiotic combined) trended toward slightly larger effects than probiotic-alone.

3.4 The honest pooled magnitude

Across all three syntheses, the pooled probiotic effect on body weight in overweight/obese adults is approximately 0.5-1 kg over 8-24 weeks, with a BMI reduction of approximately 0.27-0.30 kg/m². This is statistically detectable but clinically modest. It is not zero. It is also not transformative. Realistic expectations for any commercial probiotic, including Bioma, sit within this range — not above it.

4. The strongest single trial: Stenman 2016 B420 + polydextrose

Stenman and colleagues (2016, PMID 27810310, EBioMedicine) conducted the single most-cited probiotic-and-body-fat trial in the adult overweight/obesity literature. The design:

• Population: 225 healthy adults with overweight or obesity (mean BMI ~32 kg/m²)
• Design: 6-month, four-arm, randomized, double-blind, placebo-controlled trial
• Arms:
  • Placebo
  • B. animalis ssp. lactis 420 (10^10 CFU/day) alone
  • Polydextrose (12 g/day) alone (prebiotic-only arm)
  • B420 + polydextrose combination
• Primary outcomes: body fat mass (DXA), body weight, waist circumference, serum zonulin

4.1 Findings

• Body fat mass: the combination arm (B420 + polydextrose) reduced relative fat mass by 4.5% versus placebo; the B420-only arm reduced it by 3.1% versus placebo. Both reached statistical significance.
• Waist circumference: significant reductions in the combination and B420-only arms.
• Body weight: the body-weight differences favored the active arms but did NOT reach statistical significance — the effect was on body composition (more fat loss, less lean-mass loss) without a strong scale-weight signal.
• Trunk fat: the largest individual region of fat loss in the combination arm.
• Serum zonulin (gut permeability marker): reductions in the active arms, supporting a gut-barrier-integrity mechanism.

4.2 What this means for Bioma

Stenman 2016 is the closest published evidence to a meaningful body-composition effect from a specific commercial probiotic strain. But the trial used:

• The specific strain B. animalis ssp. lactis 420 (DuPont/IFF strain), NOT one of the unspecified B. lactis variants in Bioma
• 12 g/day of polydextrose — a higher dose of a different prebiotic than Bioma's 100 mg XOS
• A 10^10 CFU/day dose of B420
• A 6-month treatment duration — far longer than Bioma's 14-day money-back guarantee allows for evaluation

The reasonable interpretation: Stenman 2016 demonstrates that some probiotic strains, at specific doses, paired with specific prebiotics, for at least 6 months, can produce a measurable but modest reduction in body fat mass. This does NOT automatically transfer to Bioma's different strain mixture at different doses with a different prebiotic for a 30-day trial period. The Stenman 2016 result is suggestive, not predictive, of Bioma's likely effect.

5. Akkermansia muciniphila: the hot strain and what the only RCT actually shows

Akkermansia muciniphila is a Gram-negative, mucin-degrading bacterium that comprises 1-4% of the healthy adult colonic microbiome. Observational studies have repeatedly correlated higher A. muciniphila abundance with lower body weight, lower insulin resistance, and lower systemic inflammation. The bacterium has been featured heavily in recent gut-microbiome marketing, including Bioma's GLP-1 Booster product, which lists 10 mg of Akkermansia muciniphila per serving.

5.1 Depommier 2019 (Nature Medicine) — the only human RCT

Depommier and colleagues (2019, PMID 31263284, Nature Medicine) conducted the first and (as of the May 2026 verified literature) only randomized, placebo-controlled clinical trial of A. muciniphila supplementation in humans:

• Design: 3-month, randomized, double-blind, placebo-controlled pilot
• Population: 32 overweight/obese adults with insulin resistance and metabolic syndrome features
• Intervention: live A. muciniphila (10^10 cells/day), or pasteurized A. muciniphila (10^10 cells/day, heat-killed but membrane-protein-intact), or placebo

Findings:

• Insulin sensitivity (HOMA-IR): significantly improved in the pasteurized A. muciniphila arm versus placebo
• Plasma total cholesterol: reduced in the pasteurized arm
• Body weight: trend toward reduction of approximately 2.27 kg in the pasteurized arm versus placebo — did NOT reach statistical significance
• Inflammatory markers: reductions in some markers of low-grade inflammation

What this means and does NOT mean: Depommier 2019 is a small (n=32), short (3 months), proof-of-concept pilot. It demonstrates that pasteurized A. muciniphila is safe at 10^10 cells/day and that it can produce measurable metabolic effects. It was NOT powered as a weight-loss efficacy trial. The body-weight effect was a trend, not a confirmed result. A larger, longer Phase 2 program would be required to determine whether A. muciniphila supplementation produces clinically meaningful weight loss.

5.2 The 10 mg dose question

Bioma's GLP-1 Booster lists 10 mg of A. muciniphila per serving. Depommier 2019 used 10^10 cells per day (10 billion cells). Whether 10 mg of dried A. muciniphila biomass in Bioma corresponds to the 10^10 cells used in the Depommier trial depends on:

• Whether the 10 mg is live cells, pasteurized cells, or some fraction of either
• The specific cell count per mg of biomass (manufacturer-dependent)
• The stability and viability through gastric acid (typically addressed via delayed-release capsule or specific formulation technology)

Bioma does not publicly disclose CFU or cells per mg for the Akkermansia component on the GLP-1 Booster product page. Consumers who want to match the Depommier 2019 dose cannot verify whether Bioma's product delivers it.

5.3 The “GLP-1 Booster” naming

Marketing a probiotic as a “GLP-1 Booster” implies functional augmentation of endogenous or exogenous GLP-1 signaling. There is preliminary mechanistic evidence that gut microbiota modulate endogenous incretin production via short-chain fatty acids and bile-acid signaling. There is NO peer-reviewed human RCT demonstrating that any commercial probiotic, including Bioma's GLP-1 Booster, augments the efficacy of an FDA-approved GLP-1 receptor agonist (Wegovy, Ozempic, Mounjaro, Zepbound, Foundayo, or Saxenda) for weight loss or glycemic control. The “booster” framing is a marketing claim that exceeds the published evidence.

6. The XOS prebiotic and tributyrin postbiotic

6.1 Xylooligosaccharide (XOS, 100 mg)

Xylooligosaccharide is a non-digestible carbohydrate prebiotic derived from corncobs, bamboo shoots, or other plant-cell-wall sources. It is selectively fermented by Bifidobacterium species in the colon, producing short-chain fatty acids (mostly acetate and butyrate). Human studies typically use doses in the 1-4 g/day range to demonstrate measurable shifts in fecal Bifidobacteria abundance over 4-12 weeks. Bioma's 100 mg/day dose is approximately 10-40-fold lower than typical research doses. At 100 mg, the prebiotic effect on Bifidobacterium populations is likely small. The XOS in Bioma may function more as a capsule-stability or marketing-claim ingredient than as a clinically active prebiotic dose.

6.2 Tributyrin (CoreBiome, 90 mg)

Tributyrin is a glycerol-bound triester of butyric acid — a stable lipid form of butyrate that delivers SCFA (short-chain fatty acid) precursor through the upper GI tract. Butyrate is a key energy substrate for colonocytes (the cells lining the colon), has documented effects on gut-barrier function, mucin production, and local inflammation in cell and animal models. Human RCT evidence for oral tributyrin supplementation is sparse. The most recent peer-reviewed human trial is Korenblik 2025 (PMID 41248397, BMJ Open), an 8-week feasibility and acceptability study of oral tributyrin as add-on to antidepressant medication. There is NO published RCT demonstrating that 90 mg/day of oral tributyrin produces meaningful weight loss in humans.

The tributyrin component is mechanistically reasonable as a gut-barrier-and-colonocyte-substrate intervention. The dose in Bioma is at the low end of the research-relevant range. There is no evidence base to make a weight-loss claim from tributyrin alone.

7. Bioma vs FDA-approved anti-obesity medications: the order-of-magnitude gap

The most important context for any “does X work for weight loss” question is the magnitude of the effect compared to the best-available interventions. The benchmarks:

Per-kg-lost cost comparison (rough order of magnitude over 12 months for a 100-kg adult):

• Bioma at $40/month × 12 months = $480 spent for an expected ~0.5-1 kg loss (probiotic-class pooled magnitude, not Bioma-specific) → $480-$960 per kg lost
• Berberine at $20/month × 12 months = $240 spent for ~2 kg loss → $120 per kg lost
• Zepbound LillyDirect at $499/month × 12 months = $5,988 spent for ~20 kg loss → $299 per kg lost
• Wegovy with commercial-insurance copay card at $25/month × 12 months = $300 spent for ~15 kg loss → $20 per kg lost

For patients who medically qualify and can access insurance coverage, FDA-approved AOMs deliver weight loss at approximately 1/20th to 1/50th the per-kg cost of a commercial probiotic like Bioma. For patients without coverage, self-pay LillyDirect Zepbound vials still deliver weight loss at lower per-kg cost than Bioma on subscription.

This is the order-of-magnitude reality of the comparison. Bioma is not a substitute for, equivalent to, or in the same therapeutic-impact category as an FDA-approved AOM. It is a food-class supplement with food-class effects.

8. Side effects, drug interactions, and who should NOT take Bioma

8.1 Common, mild side effects

For healthy adults, probiotic supplements including Bioma are generally well tolerated. The most common adverse events documented across the probiotic class:

• Bloating, gas, flatulence — typically in the first 1-2 weeks of starting a new probiotic as the microbiome adjusts; usually self-limiting
• Mild abdominal discomfort or transient changes in stool consistency
• Increased belching in some users, particularly with multi-strain blends
• Headache rarely reported with histamine-producing strains

8.2 Rare but serious adverse events

Doron and Snydman (2015, PMID 25922398, Clinical Infectious Diseases) reviewed the risk and safety of probiotics. The documented serious adverse events — bacteremia, fungemia, endocarditis, and probiotic-associated sepsis — have been reported almost exclusively in:

• Severely immunocompromised patients (organ transplant recipients on immunosuppression, advanced HIV with low CD4, active chemotherapy with neutropenia)
• Premature infants in neonatal intensive care
• Patients with central venous catheters — risk of catheter colonization
• Patients with severe acute pancreatitis — the 2008 PROPATRIA trial (Besselink et al., Lancet) showed an increased mortality signal in this specific population with a specific multi-species probiotic
• Patients with short bowel syndrome or other major GI surgery
• Recent major cardiac surgery

Practical implication: Bioma at the labeled dose in a healthy adult has a favorable safety profile. Bioma in any of the high-risk populations above should be discussed with the treating physician first. The absolute risk in any individual remains low, but the consequence of a probiotic-associated bloodstream infection in an immunocompromised host can be severe.

8.3 Drug interactions

Probiotic drug interactions are not well-characterized in the formal pharmacology literature. The most discussed pairings:

• Antibiotics: Suez and colleagues (2018, PMID 30193113, Cell) found that post-antibiotic probiotic supplementation in healthy adults actually IMPAIRED native gut-microbiome reconstitution compared with no probiotic and with autologous fecal microbiota transplant. The implication: routinely taking a probiotic immediately after a course of antibiotics may not be the obvious benefit it appears to be, and may slow the return of an individual's diverse native microbiome. This is counterintuitive to common consumer advice but is the published finding.
• Immunosuppressants: patients on tacrolimus, cyclosporine, mycophenolate, corticosteroids at immunosuppressive doses, or biologic immunosuppressants should discuss any probiotic with their transplant or rheumatology team. The risk of probiotic-associated bacteremia is higher in immunosuppressed patients.
• GLP-1 receptor agonists (Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Foundayo): no documented pharmacokinetic or pharmacodynamic interaction. The mechanisms are independent. As of the May 2026 verified literature, there is NO peer-reviewed RCT of any commercial probiotic co-administered with a GLP-1 RA for weight-loss enhancement. Practical caution: start one new intervention at a time so you can attribute any GI symptoms (nausea, bloating, constipation) correctly. See our GLP-1 nausea management guide for the differential.
• Acid-suppressing therapy (PPIs, H2 blockers): theoretical interaction — reduced gastric acid can affect upper-GI viability of orally administered probiotics. Bioma uses delayed-release capsules which partially mitigate this. The clinical significance of the interaction is unclear.

9. Who might reasonably benefit from Bioma (and who probably won't)

9.1 Reasonable use cases

• Functional bloating without identifiable IBS, SIBO, or food intolerance: a 1-3 month probiotic trial is a defensible self-experiment. Effect sizes for general probiotic-class supplementation on bloating and gas are real but modest.
• Mild, occasional constipation in healthy adults: probiotic supplementation can modestly improve stool frequency and consistency. (Dietary fiber, hydration, and physical activity are higher-yield interventions.)
• Following a course of antibiotics: evidence is mixed (see Suez 2018, PMID 30193113), with some indication that routine post-antibiotic probiotic use may slow native microbiome recovery. Discuss with your physician if symptomatic GI distress persists.
• Travelers' diarrhea prophylaxis: certain specific strains (S. boulardii, L. rhamnosus GG) have evidence; Bioma's specific blend does not match those evidence-based strains.

9.2 NOT reasonable use cases (where Bioma will not deliver the advertised effect)

• Weight loss as the primary goal: the expected effect is approximately 0.5-1 kg over months, dwarfed by every other intervention. Spend the budget on the higher-yield interventions in Section 10.
• “Targeting belly fat”: spot reduction is not a documented physiological mechanism. The Stenman 2016 trial did show preferential trunk-region fat reduction with B420 + polydextrose, but this is one trial with one specific strain that is NOT in Bioma.
• Augmenting Wegovy / Ozempic / Zepbound / Mounjaro / Foundayo efficacy: no published trial supports this. Save the monthly cost.
• Replacing a GLP-1 medication for which you have a medical indication: Bioma at every dose level is approximately 25-50x less effective than Wegovy or Zepbound. It is not a substitute for a medically indicated AOM.
• Treating diagnosed IBD, IBS, celiac, SIBO, or C. difficile: see a gastroenterologist. Evidence-based prescription protocols exist for each of these. Self-treating with a consumer probiotic is at best secondary and at worst delays proper diagnosis.

10. What actually works for weight loss (the evidence-based budget allocation)

If $30-$50 per month is what you have to spend on weight management, the order-of-effectiveness allocation is:

10.1 Adequate protein at every meal

1.2-1.6 g/kg body weight per day per ACSM and ISSN guidelines, distributed across 3-4 meals. Complete proteins (chicken, fish, eggs, dairy, soy, legumes, whey/plant blends) at every meal. This is the single largest dietary lever for both weight loss and lean-mass preservation. A $30/month whey or plant-protein supplement investment outperforms a probiotic for satiety, lean mass, and metabolic-rate preservation by an order of magnitude. Use our GLP-1 protein calculator to find your specific daily target.

10.2 Resistance training (lean-mass preservation)

≥2 days per week of resistance training plus 250+ minutes per week of moderate aerobic activity (ACSM 2009 / HHS 2018 Physical Activity Guidelines). For GLP-1 users specifically, where 25-39% of weight loss is lean tissue absent intervention, resistance training is the single most defensible add-on. See our exercise pairing for lean-mass preservation for the complete weekly program.

10.3 Caloric awareness (food logging)

A $15-$30/month food-logging app subscription (MyFitnessPal, Cronometer, Lose It, Carbon, Macros). The “measurement intervention” effect of calorie tracking is among the most replicated behavioral nutrition findings. Pair with structured meal planning or a macronutrient-based dietary pattern.

10.4 FDA-approved AOMs for qualifying patients

For patients with BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity, FDA-approved anti-obesity medications deliver order-of-magnitude greater weight loss than any supplement:

• Wegovy (semaglutide 2.4 mg weekly) — ~15% TBWL over 68 weeks (STEP-1, PMID 33567185)
• Zepbound (tirzepatide 5/10/15 mg weekly) — ~21% TBWL at 15 mg over 72 weeks (SURMOUNT-1, PMID 35658024)
• Saxenda (liraglutide 3 mg daily) — ~8% TBWL over 56 weeks
• Foundayo (orforglipron, oral GLP-1 RA) — ~12-14% TBWL based on ATTAIN-1 data
• LillyDirect self-pay Zepbound vials at $349 (2.5 mg) to $499 (15 mg) per month for patients without insurance coverage

Discuss eligibility with your prescriber. See our GLP-1 insurance coverage guide for the navigation framework.

10.5 If you still want a supplement: prioritize evidence-graded picks

See our supplements evidence-graded review for the 16-supplement framework. The grade-A and grade-B picks (berberine, MCT oil, glucomannan, green tea catechins, psyllium) are all cheaper than Bioma per month and have larger pooled evidence bases for body weight specifically.

11. The DSHEA regulatory framework (what consumers should know)

All probiotics sold over-the-counter in the United States, including Bioma, are regulated under the Dietary Supplement Health and Education Act of 1994 (DSHEA). Under DSHEA:

• Manufacturers determine safety: dietary supplement manufacturers are responsible for ensuring their products are safe before marketing. The FDA does NOT review supplements for safety before they reach the market.
• No pre-market efficacy review: the FDA does NOT review dietary supplements for efficacy before marketing. Supplements can claim “structure-function” effects (“supports gut health,” “promotes a healthy microbiome”) without prior FDA approval, but cannot claim to diagnose, treat, cure, or prevent specific diseases.
• Labeling and manufacturing rules apply: manufacturers must follow current Good Manufacturing Practices (cGMPs) under 21 CFR Part 111, list ingredients and serving sizes, and include the mandatory DSHEA disclaimer.
• FDA can act post-market: the FDA can issue warning letters, seizures, or injunctions against products that are adulterated, misbranded, or unsafe, but this is generally a post-market enforcement model rather than pre-market review.

What this means for the Bioma consumer: when the Bioma website says “Powerful weight-loss boost,” the FDA has not reviewed or validated that claim. The mandatory DSHEA disclaimer at the bottom of the page (“This product is not intended to diagnose, treat, cure, or prevent any disease”) is the regulatory acknowledgment that this is a food-class product, not an evidence-validated weight-loss therapeutic. The structure-function claim is legal under DSHEA; it is also not the same standard as the efficacy demonstrations required of FDA-approved drugs like Wegovy and Zepbound.

The FDA periodically publishes consumer alerts about deceptive weight-loss marketing (the “Beware of Products Promising Miracle Weight Loss” consumer update, last revised 2024). The FTC operates the “Gut Check” framework for evaluating weight-loss advertising claims and considers claims like “lose weight without diet or exercise” to be inherently false. Bioma does NOT make explicit Gut-Check-flagged claims, but its “powerful weight-loss boost” and “blocks excess fat storage” language operates close to the structure-function line.

Frequently asked questions